Methylation and polygenic risk scores capture different features of systemic lupus erythematosus
Clicks: 1
ID: 320733
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #149 of 197 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 197 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: The aetiopathogenesis of SLE encompasses genetic, environmental and epigenetic factors. We investigated associations between an SLE methylation risk score (MRS), HLA-DRB1*03:01, a non-HLA polygenic risk score (PRS) and clinical and immunological phenotypes. METHODS: DNA methylation in whole blood from patients fulfilling ≥4 ACR-82 criteria and controls were investigated using the Illumina HM450K array. The discovery cohort included 311 patients and 400 controls, and the replication cohort comprised 175 patients and 187 controls. Seventeen independent, top differentially methylated CpG sites (Δβ of ≥ 0.1) from case-control comparisons, were used to calculate the MRS. Genotyping was performed using the Immunochip, and the PRS included 57 non-HLA SLE SNVs. Clinical data were collected from patient charts, and serum IFN-α2 was measured using Simoa. RESULTS: Higher MRS was strongly associated with serum IFN-α2 levels (p = 1.04 × 10-14). In both cohorts, higher MRS associated with discoid lupus, immunologic involvement, and anti-SSA/SSB/RNP/Sm autoantibodies (all p < 0.05), and with higher disease activity in the discovery cohort (p = 1.50 × 10-4). MRS was also elevated in patients with multiple autoantibodies (p < 1.0 × 10-15) and in HLA-DRB1*03:01 carriers (p < 1.0 × 10-3). In contrast, higher PRS was associated with nephritis, anti-dsDNA positivity, and lower prevalence of anti-SSB antibodies (all p < 0.05). No correlation was observed between the MRS and the PRS (p = 0.35). CONCLUSION: The MRS defines an interferon-high, HLA-DRB1*03:01-linked SLE subset with multiple autoantibodies, partly distinct from PRS-associated nephritis risk, highlighting potentially divergent pathogenic pathways. These findings underscore the value of integrating genetic and epigenetic data to better understand underlying disease mechanisms in SLE.
| Reference Key |
openalex_W7168034291
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Holme Vestin, Nina Oparina, Maija-Leena Eloranta, Elisabeth Skoglund, Ioanna Giannakou, Martina Frodlund, Iva Gunnarsson, C Sjöwall, Elisabet Svenungsson, Lars Rönnblom, Juliana Imgenberg‐Kreuz, D Leonard |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag359
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.